Core Insights - Crocs (CROX) is expected to report quarterly earnings of $2.37 per share, a decline of 34.2% year-over-year, with revenues forecasted at $965.11 million, reflecting a 9.1% decrease compared to the same period last year [1] - The consensus EPS estimate has been revised 5.8% lower in the last 30 days, indicating a collective reevaluation by analysts [2] - Analysts emphasize the importance of earnings estimate revisions as a predictor of investor actions and short-term stock performance [3] Revenue Projections - Revenues for the Crocs Brand are projected to be $819.18 million, down 4.5% from the prior-year quarter [5] - HEYDUDE Brand revenues are estimated at $145.51 million, indicating a significant year-over-year decline of 28.7% [5] - HEYDUDE Brand Wholesale revenues are expected to be $65.23 million, reflecting a 42.3% decrease year-over-year [5] Channel-Specific Revenue Estimates - Direct-to-Consumer revenues for the Crocs Brand are estimated at $433.31 million, a decline of 6.3% year-over-year [6] - Direct-to-Consumer revenues for the HEYDUDE Brand are projected at $82.08 million, suggesting a 9.9% decrease year-over-year [6] - Wholesale revenues for the Crocs Brand are expected to reach $387.87 million, indicating a 2% decline year-over-year [6] Stock Performance - Crocs shares have increased by 4.2% over the past month, outperforming the Zacks S&P 500 composite, which rose by 3.6% [7] - The company holds a Zacks Rank 4 (Sell), suggesting it is expected to underperform the overall market in the near term [7]

Core Viewpoint - Boston Scientific (BSX) shares have increased by 3% recently, closing at $101.11, with analysts suggesting a potential upside of 25.6% based on a mean price target of $127 [1] Price Targets and Analyst Consensus - The average price target consists of 31 estimates, ranging from a low of $113.00 to a high of $140.00, with a standard deviation of $6.38, indicating a relatively high agreement among analysts [2] - The lowest estimate suggests an 11.8% increase, while the highest indicates a 38.5% upside [2] - A low standard deviation signifies strong consensus among analysts regarding BSX's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about BSX's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the past 30 days, the Zacks Consensus Estimate for the current year has risen by 2%, with 10 estimates moving higher and no negative revisions [12] - BSX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Implications of Price Targets - While the consensus price target may not be a reliable predictor of BSX's potential gains, the direction indicated by these targets appears to be a useful guide for further research [14]

Core Insights - Eli Lilly (LLY) is expected to report quarterly earnings of $6.02 per share, reflecting a year-over-year increase of 410.2% [1] - Revenue projections stand at $16.01 billion, indicating a 40% increase from the same quarter last year [1] - The consensus EPS estimate has been adjusted upward by 0.3% over the past 30 days, showing analysts' reassessment of their projections [1][2] Revenue Estimates - Analysts predict 'Net Sales- Cyramza (Ramucirumab /IMC-1121B)' will reach $237.79 million, a year-over-year change of +0.8% [4] - 'Net Sales- Humulin' is estimated at $180.73 million, reflecting a decline of -12.7% year over year [4] - 'Net Sales- Humalog' is projected at $512.59 million, indicating a decrease of -4.1% from the previous year [4] Additional Sales Projections - 'Net Sales- Forteo' is expected to be $96.63 million, down -18.2% year over year [5] - 'Net Sales- Cyramza (Ramucirumab /IMC-1121B)- US' is forecasted at $107.96 million, suggesting a +1.4% change year over year [5] - 'Net Sales- International- Humalog' is estimated at $212.55 million, reflecting a +0.8% change from the year-ago quarter [5] Geographic Revenue Insights - 'Net Sales- International- Forteo' is projected at $40.97 million, indicating a -11.7% change year over year [6] - 'Net Sales- Humulin- US' is expected to reach $126.25 million, down -15.8% from the previous year [6] - 'Geographic Revenue- United States' is forecasted to be $11.13 billion, suggesting a +42.5% year-over-year increase [7] Market Performance - Over the past month, Lilly shares have increased by +13.9%, outperforming the Zacks S&P 500 composite's +2.5% change [8] - Based on its Zacks Rank 3 (Hold), LLY is expected to perform in line with the overall market in the upcoming period [8]

Core Insights - Altria (MO) is expected to report quarterly earnings of $1.44 per share, reflecting a 4.4% increase year-over-year, while revenues are forecasted at $5.32 billion, indicating a 0.4% decline compared to the previous year [1] - Analysts have revised the consensus EPS estimate down by 0.3% over the last 30 days, suggesting a reevaluation of initial estimates by analysts [1][2] Revenue Estimates - Revenues net of excise taxes for Oral tobacco products are projected to be $713.65 million, showing a year-over-year increase of 2.7% [4] - Revenues net of excise taxes for Smokeable Products are expected to reach $4.64 billion, reflecting a slight decline of 0.2% from the same quarter last year [4] Operating Income Estimates - Operating Income for Oral tobacco products is estimated at $486.18 million, compared to $464.00 million from the previous year [5] - Adjusted Operating Income for Smokeable Products is anticipated to be $3.00 billion, up from $2.94 billion reported in the same quarter last year [5] Stock Performance - Altria shares have decreased by 1.6% over the past month, contrasting with a 2.5% increase in the Zacks S&P 500 composite [5] - The company holds a Zacks Rank 2 (Buy), indicating expectations of outperforming the overall market in the near term [5]

Core Viewpoint - Garmin (GRMN) is expected to report quarterly earnings of $1.98 per share, reflecting a slight decline of 0.5% year-over-year, while revenues are forecasted to increase by 12.8% to $1.79 billion [1] Earnings Estimates - There have been no revisions in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [1][2] Key Metrics Projections - Analysts project 'Net Sales- Marine' to be $239.52 million, a year-over-year increase of 7.8% [4] - 'Net Sales- Aviation' is estimated at $219.19 million, reflecting a 7.1% increase from the previous year [4] - 'Net Sales- Fitness' is expected to reach $593.93 million, showing a significant growth of 28% year-over-year [4] - 'Net Sales- Outdoor' is forecasted at $565.76 million, indicating a 7.5% increase [5] - 'Net Sales- Auto OEM' is estimated at $171.22 million, a modest increase of 1.5% [5] Operating Income Projections - 'Operating income (loss)- Outdoor' is projected to be $202.47 million, down from $208.87 million in the previous year [5] - 'Operating income (loss)- Fitness' is expected to reach $165.69 million, up from $147.77 million year-over-year [6] - 'Operating income (loss)- Marine' is forecasted at $46.17 million, an increase from $37.84 million in the prior year [6] Gross Profit Estimates - 'Gross profit- Fitness' is projected to be $352.82 million, compared to $283.33 million in the same quarter last year [7] - 'Gross profit- Marine' is estimated at $132.91 million, up from $122.43 million year-over-year [7] - 'Gross profit- Aviation' is expected to reach $164.32 million, an increase from $154.14 million in the previous year [7] - 'Gross profit- Outdoor' is projected at $366.21 million, compared to $358.69 million last year [8] Stock Performance - Garmin shares have increased by 5.7% over the past month, outperforming the S&P 500 composite, which rose by 1.3% [8]

Core Insights - Canadian Pacific Kansas City (CP) is expected to report quarterly earnings of $0.81 per share, reflecting an 11% year-over-year increase, with revenues projected at $2.68 billion, a 2.8% increase compared to the previous year [1] - The consensus EPS estimate has been revised upward by 0.6% over the past 30 days, indicating a reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3] Financial Metrics - Analysts predict an 'Adjusted Operating Ratio' of 60.4%, down from 62.9% in the same quarter last year [5] - 'Carloads - Total' are expected to reach 1.13 million, compared to 1.09 million in the same quarter last year [5] - The consensus estimate for 'Carloads - Automotive' is 63.13 thousand, slightly down from 63.70 thousand in the previous year [6] - 'Revenue ton miles (RTMs) - Total' is projected to be 54.58 billion, up from 51.52 billion in the same quarter last year [6] - 'Carloads - Grain' are expected to reach 133.62 thousand, compared to 127.00 thousand in the same quarter last year [7] - 'Carloads - Coal' are projected at 125.92 thousand, up from 121.70 thousand in the previous year [7] - 'Carloads - Potash' are expected to be 51.18 thousand, compared to 40.60 thousand last year [8] - 'Carloads - Fertilizers and Sulphur' are projected at 16.36 thousand, up from 15.60 thousand in the previous year [8] - 'Carloads - Forest Products' are expected to be 32.95 thousand, down from 33.90 thousand last year [9] - 'Carloads - Energy, Chemicals and Plastics' are projected at 138.95 thousand, down from 145.60 thousand in the previous year [9] - 'Carloads - Metals, Minerals and Consumer Products' are expected to reach 124.36 thousand, down from 127.90 thousand last year [10] - The expected 'Operating Ratio' is 59.7%, significantly improved from 66.1% in the previous year [10] Market Performance - Over the past month, Canadian Pacific Kansas City shares have returned +2.3%, outperforming the Zacks S&P 500 composite's +1.3% [11] - The company holds a Zacks Rank 4 (Sell), indicating a likely underperformance compared to the overall market in the upcoming period [11]

Core Insights - Fiserv (FI) is expected to report quarterly earnings of $2.65 per share, reflecting a 15.2% increase year-over-year, with revenues projected at $5.38 billion, a 10.1% increase from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 0.6% in the last 30 days, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts project 'Adjusted Revenue- Financial Solutions' to reach $2.59 billion, a 7.4% increase from the prior year [5]. - 'Adjusted Revenue- Merchant Solutions' is expected to be $2.83 billion, indicating a 14.4% increase year-over-year [5]. - 'Revenue- Processing and services' is forecasted at $4.67 billion, a 10.2% increase from the previous year [6]. - 'Revenue- Product' is anticipated to be $1.11 billion, reflecting a 13.9% increase [6]. - 'Revenue- Corporate and Other' is estimated at $330 million, showing a slight decline of 1.2% from the prior year [6]. Operating Income Expectations - 'Operating income- Financial Solutions' is expected to reach $1.29 billion, up from $1.14 billion in the same quarter last year [7]. - 'Operating income- Merchant Solutions' is projected at $1.01 billion, compared to $931 million in the previous year [7]. Stock Performance - Fiserv shares have returned -3.7% over the past month, contrasting with the Zacks S&P 500 composite's +1.3% change [7]. - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [7].

Core Viewpoint - Vertex (VERX) shows potential for significant upside, with a mean price target of $37.36 indicating a 44.5% increase from its current price of $25.86 [1] Price Targets - The average of 14 short-term price targets ranges from a low of $28.00 to a high of $54.00, with a standard deviation of $8.35, suggesting variability in analyst estimates [2] - The lowest estimate indicates an 8.3% increase, while the highest suggests an upside of 108.8% [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement [9] Analyst Insights - Solely relying on consensus price targets for investment decisions may not be prudent due to historical inaccuracies in predictions [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8] Earnings Estimates - Analysts are increasingly optimistic about VERX's earnings prospects, as indicated by upward revisions in EPS estimates [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.2%, with no negative revisions [12] - VERX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion - While consensus price targets may not reliably indicate the extent of potential gains, they can provide a directional guide for further research [14]

Core Insights - Mondelez (MDLZ) is expected to report quarterly earnings of $0.73 per share, reflecting a decline of 26.3% year-over-year, while revenues are forecasted to reach $9.74 billion, indicating a 5.9% increase compared to the previous year [1] - Analysts have revised the consensus EPS estimate downward by 0.5% over the past 30 days, indicating a collective reassessment of projections [1][2] Revenue Estimates - North America revenue is projected at $2.77 billion, showing a year-over-year decline of 1.8% [4] - Europe revenue is expected to reach $3.67 billion, reflecting a year-over-year increase of 10.5% [4] - AMEA revenue is estimated at $2.04 billion, indicating a 10.4% increase from the prior year [4] - Latin America revenue is forecasted at $1.25 billion, representing a 4% increase year-over-year [5] Operating Income Estimates - AMEA Non-GAAP operating income is projected at $298.89 million, down from $348.00 million in the same quarter last year [5] - Europe Non-GAAP operating income is estimated at $500.65 million, compared to $761.00 million a year ago [6] - North America Non-GAAP operating income is expected to be $491.07 million, down from $593.00 million in the previous year [6] - Latin America Non-GAAP operating income is forecasted at $125.54 million, compared to $142.00 million in the same quarter last year [7] Stock Performance - Mondelez shares have decreased by 3.8% over the past month, contrasting with a 0.2% increase in the Zacks S&P 500 composite [7] - The company holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market in the near term [7]

Core Insights - Analysts project Regeneron (REGN) will report quarterly earnings of $9.54 per share, reflecting a year-over-year decline of 23.4% [1] - Revenue is expected to reach $3.6 billion, down 3.3% from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised downward by 2% over the past 30 days, indicating a collective reassessment by analysts [2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [3] Revenue Projections - Analysts estimate 'Revenues- Libtayo- Total' at $370.10 million, a year-over-year increase of 28.2% [5] - 'Revenues- Other Revenue' is projected at $131.84 million, reflecting a 15.5% increase from the previous year [5] - 'Revenues- Net product sales' are expected to be $1.57 billion, showing a decline of 19.3% year over year [5] Specific Product Revenues - 'Revenues- Collaboration' is estimated at $1.85 billion, indicating an 11.6% year-over-year increase [6] - 'Revenues- Eylea (Aflibercept)- US' is projected at $1.09 billion, down 28.9% from the year-ago quarter [6] - 'Revenues- Dupixent (dupilumab)- US' is expected to reach $3.40 billion, reflecting a 20.4% increase year over year [8] Market Performance - Over the past month, Regeneron shares have returned +1.3%, outperforming the Zacks S&P 500 composite's +0.2% change [8] - Currently, REGN holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [9]